	US 12,109,265 B2
	Drug regimen for treatment of cerebral ischemia
Lawrence M. Kauvar, San Francisco, CA (US); and Damir Janigro, Cleveland Heights, OH (US)
Assigned to Shimojani, LLC, Pray, MT (US)
Filed by Shimojani, LLC, Pray, MT (US)
Filed on Aug. 2, 2021, as Appl. No. 17/392,144.
Application 17/392,144 is a division of application No. 16/842,458, filed on Apr. 7, 2020.
Application 16/842,458 is a continuation of application No. 15/859,075, filed on Dec. 29, 2017, granted, now 10,617,756, issued on Apr. 14, 2020.
Claims priority of provisional application 62/470,086, filed on Mar. 10, 2017.
Claims priority of provisional application 62/442,826, filed on Jan. 5, 2017.
Prior Publication US 2021/0361769 A1, Nov. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/22 (2006.01); A61K 38/49 (2006.01); A61K 39/395 (2006.01); A61P 9/10 (2006.01); G01N 33/49 (2006.01)

CPC A61K 39/3955 (2013.01) [A61K 38/49 (2013.01); A61P 9/10 (2018.01); C07K 16/22 (2013.01); G01N 33/491 (2013.01); C12Y 304/21031 (2013.01); C12Y 304/21068 (2013.01); C12Y 304/21073 (2013.01)]

11 Claims

1. A method of treatment to reduce neuronal damage caused by a cerebral ischemic event in a human patient, said method comprising administering to said patient an effective amount of a thrombolytic agent and an effective amount of an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction (VEGF-RST), wherein

(i) the inhibitor is selected from the group consisting of ranibizumab and bevacizumab, and wherein the effective amount of the inhibitor is 0.1-2.5 mg in a 70 kg patient with adjustments for patients of different weights;

(ii) the effective amount of said inhibitor provides inhibition of >50% of said VEGF-RST activity over 24 hours; and

(iii) the serum concentration level of said inhibitor is reduced below this pharmacologically active level at least by 48 hours after administration.